Crossmark Global Holdings Inc. Sells 3,484 Shares of Haemonetics Co. (NYSE:HAE)

Crossmark Global Holdings Inc. cut its holdings in shares of Haemonetics Co. (NYSE:HAE) by 34.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,514 shares of the medical instruments supplier’s stock after selling 3,484 shares during the period. Crossmark Global Holdings Inc.’s holdings in Haemonetics were worth $524,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP acquired a new position in shares of Haemonetics during the second quarter worth approximately $39,000. Covestor Ltd lifted its holdings in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Haemonetics in the 2nd quarter valued at $82,000. Canada Pension Plan Investment Board bought a new stake in shares of Haemonetics during the second quarter worth $83,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Haemonetics during the first quarter valued at $86,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

HAE opened at $89.22 on Friday. The stock has a market cap of $4.48 billion, a P/E ratio of 37.02, a P/E/G ratio of 1.43 and a beta of 0.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The company has a fifty day simple moving average of $77.55 and a 200 day simple moving average of $82.75.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. During the same period in the prior year, the company earned $0.99 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, research analysts expect that Haemonetics Co. will post 4.59 EPS for the current year.

Analyst Upgrades and Downgrades

HAE has been the subject of several recent research reports. Bank of America started coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company. Citigroup cut their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Finally, BTIG Research assumed coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.